journal
preproof
j
u
r
n
l
p
r
e
p
r
f
abstract
object
pandem
consum
consider
resourc
impact
deliveri
cancer
care
patient
cancer
may
factor
place
high
risk
covid
morbid
mortal
highli
immunosuppress
chemotherapi
regimen
possibl
exposur
treatment
may
put
patient
addit
risk
societi
gynecolog
oncolog
conven
expert
panel
address
recommend
best
practic
crisi
minim
risk
patient
deviat
cancer
care
morbid
method
expert
panel
conven
develop
initi
consensu
guidelin
regard
antineoplast
therapi
pandem
respect
gynecolog
cancer
care
clinic
trial
result
pose
special
risk
patient
older
medic
comorbid
cancer
addit
pandem
like
strain
resourc
make
deliveri
cancer
care
conduct
clinic
trial
unpredict
recommend
limit
visit
contact
health
care
facil
use
telemedicin
appropri
choos
regimen
requir
less
frequent
visit
less
immunosuppress
deviat
occur
clinic
trial
result
limit
resourc
import
understand
regulatori
oblig
trial
sponsor
well
irb
ensur
clinic
trial
patient
safeti
oversight
maintain
ongo
crisi
strain
resourc
need
deliv
cancer
care
alter
deliveri
care
mandat
effort
taken
minim
risk
maxim
safeti
approxim
standard
practic
journal
preproof
j
u
r
n
l
p
r
e
p
r
f
highlight
world
wide
pandem
limit
cancer
care
clinic
trial
strategi
employ
limit
contact
point
health
care
facil
care
consid
risk
cancer
care
balanc
risk
infect
journal
preproof
pandem
rapidli
drastic
chang
care
gynecolog
cancer
patient
regardless
geograph
locat
impact
practition
howev
degre
vari
base
burden
avail
local
resourc
given
variabl
decis
regard
cancer
care
deliveri
individu
institut
govern
mandat
priorit
base
locoregion
factor
special
consider
need
regard
decis
system
cancerdirect
therapi
clinic
trial
enrol
unpreced
time
chemotherapi
anticanc
treatment
may
result
signific
immun
compromis
patient
render
suscept
viral
infecti
ill
recent
wuhan
experi
patient
report
jama
oncolog
note
infect
rate
cancer
patient
doubl
gener
popul
ci
addit
covid
infect
contract
hospit
cancer
patient
admit
higher
risk
sever
event
composit
endpoint
percentag
patient
admit
icu
ventil
death
compar
patient
without
cancer
seven
patient
vs
patient
fisher
exact
lastli
patient
underw
chemotherapi
surgeri
within
previou
month
numer
higher
risk
sever
event
though
small
seri
report
china
differ
cancer
care
gynecolog
cancer
patient
diagnos
studi
period
find
inform
help
us
understand
potenti
risk
patient
cancer
given
inform
must
care
weigh
risk
present
patient
receiv
antineoplast
therapi
particip
clinic
trial
travel
treatment
center
interact
healthcar
team
increas
patient
risk
exposur
transmiss
cancer
treatment
caus
toxic
requir
acut
care
possibl
hospit
increas
sever
infect
risk
via
immunocompromis
nonetheless
chemotherapi
therapeut
benefit
care
deliber
requir
decisionmak
surround
anticanc
therapi
clinic
trial
manag
challeng
time
tabl
neoadjuv
chemotherapi
ovarian
cancer
compar
primari
surgic
debulk
reduc
morbid
reduc
risk
hospit
primari
surgic
debulk
especi
high
burden
area
delay
interv
debulk
surgeri
beyond
cycl
neoadjuv
chemotherapi
reduc
morbid
hospit
patient
ovarian
cancer
choos
regimen
necessit
fewest
infus
visit
ie
q
paclitaxelcarboplatin
consid
avoidinglimit
prescript
dosedens
intraperiton
hipec
regimen
consid
oral
hormon
monotherapi
patient
lowgrad
serou
ovarian
cancer
earli
endometri
cancer
treatment
progesteron
therapi
progesteron
contain
iud
may
decreas
bleed
provid
tempor
benefit
primari
surgeri
delay
lower
grade
cancer
advancedrecurr
endometri
cancer
consid
use
megestrol
acet
megestrol
acet
altern
tamoxifen
endometri
cancer
endometrioid
histolog
estrogenprogesteron
receptor
statu
posit
oral
everolimusletrozol
may
better
respons
rate
compar
hormon
therapi
alon
impact
increas
toxic
possibl
immunosuppress
consid
avoid
radiat
possibl
unless
cur
intent
ie
local
advanc
cervic
cancer
patient
recurr
cervic
cancer
receiv
prior
cisplatin
consid
paclitaxelcarboplatin
paclitaxelcisplatin
base
regimen
due
shorter
total
time
infus
center
less
toxic
j
u
r
n
l
p
r
e
p
r
f
gener
consider
outlin
tabl
tabl
util
deliber
frontlin
anticanc
therapi
specif
treatment
option
see
tabl
select
primari
treatment
earli
stage
late
stage
gynecolog
malign
respect
advanc
ovarian
cancer
decis
primari
debulk
surgeri
pd
neoadjuv
chemotherapi
nact
must
made
respect
burden
avail
resourc
care
decisionmak
regard
surgeri
util
older
patient
signific
medic
comorbid
poor
nutrit
statu
may
requir
prolong
icuhospit
stay
requir
nurs
home
facil
placement
postsurgeri
nact
avoid
mani
challeng
requir
biopsi
patholog
confirm
chemotherapi
still
result
immunocompromis
state
random
phase
trial
includ
eortc
choru
demonstr
nact
inferior
primari
surgic
cytoreduct
respect
overal
progressionfre
surviv
lower
morbid
nact
patient
advanc
stage
diseas
viabl
altern
pd
resourc
surgic
intervent
restrict
pandem
crisi
highgrad
serou
ovarian
cancer
week
taxaneplatinum
regimen
optim
dosedens
intraperiton
regimen
probabl
avoid
nact
consid
delay
interv
debulk
surgeri
beyond
cycl
reduc
surgic
morbid
hospit
high
covid
burden
area
hormon
therapi
demonstr
efficaci
low
grade
serou
ovarian
cancer
consid
transit
chemotherapi
hormon
monotherapi
progesteron
therapi
megestrol
acet
levonorgestrel
intrauterin
devic
earli
stage
grade
endometrioid
endometri
cancer
util
lieu
surgeri
due
limit
capabl
secondari
resourc
limit
advanc
stage
endometrioid
andor
hormon
receptor
posit
tumor
oral
megesterol
acet
megesterol
acet
altern
tamoxifen
util
increas
efficaci
oral
everolimu
letrozol
must
balanc
greater
toxic
immunosuppress
j
u
r
n
l
p
r
e
p
r
f
radiat
therapi
util
cur
intent
chemoradi
offer
improv
surviv
local
advanc
cervic
cancer
priorit
metastat
cervic
cancer
use
q
paclitaxel
carboplatin
reduc
total
time
infus
center
toxic
consid
overal
surviv
benefit
bevacizumab
versu
risk
fistula
hospit
cervic
cancer
two
main
class
mainten
therapi
fda
approv
ovarian
cancer
includ
iv
antiangiogen
agent
bevacizumab
oral
parpi
olaparib
niraparib
rucaparib
agent
prolong
progressionfre
surviv
one
must
consid
increment
benefit
routin
surveil
asymptomat
patient
postpon
appropri
conduct
via
telemedicin
consid
delay
start
new
therapi
patient
asymptomat
recurr
andor
recurr
ovarian
cancer
patient
patient
symptomat
recurr
diseas
choic
therapi
predic
minim
exposur
contact
risk
therapi
life
expectancyprognosi
consid
lower
dose
intens
less
myelosuppress
regimen
reduc
lymphopenia
neutropenia
exact
role
lymphopenia
neutropenia
infect
remain
unclear
lymphopenia
describ
associ
poor
outcom
sever
diseas
patient
infect
certain
patient
oral
therapi
may
prefer
altern
minim
visit
exposur
medic
set
patient
grade
endometrioid
endometri
cancer
oral
hormon
therapi
regimen
megestrol
acet
altern
megestrol
acetatetamoxifen
consid
parpi
use
treatment
brca
associ
platinumsensit
hrd
ovarian
cancer
oral
chemotherapi
etoposid
cyclophosphamid
option
patient
ovarian
cancer
one
cogniz
risk
benefit
therapi
consid
risk
potenti
complic
best
support
care
may
provid
better
outcom
patient
likelihood
benefit
therapi
low
eg
platinumrefractori
ovarian
cancer
j
u
r
n
l
p
r
e
p
r
f
patient
treat
recurr
ovarian
cancer
base
level
alon
compar
clinic
symptomat
relaps
demonstr
differ
overal
surviv
two
group
addit
case
seri
report
endometri
cancer
patient
cervic
cancer
patient
symptom
time
recurr
even
set
surveil
suggest
remot
telemedicin
visit
identifi
mani
patient
potenti
recurr
patient
chemotherapi
consid
emerg
data
report
higher
rate
infect
cancer
patient
well
increas
risk
sever
event
especi
patient
receiv
recent
cancerdirect
therapi
make
decis
proceed
therapi
recurr
diseas
choic
therapi
regimen
care
consider
must
made
regard
benefit
therapi
term
symptomat
relief
surviv
prevent
hospit
compar
risk
increas
exposur
medic
set
therapi
possibl
complic
therapi
potenti
increas
risk
infect
sever
test
corticosteroid
mainstay
treatment
irrel
pneumon
steroid
prolong
immunosuppress
increas
risk
infect
delay
viral
clearanc
increas
viral
pneumon
mortal
current
cdc
recommend
corticosteroid
use
treatment
viral
pneumonia
ard
unless
indic
anoth
reason
asthma
copd
septic
shock
care
evalu
anticip
benefit
start
immunotherapi
preexist
lymphopenia
associ
lower
immunotherapi
respons
predict
sever
infect
immunotherapi
administr
higher
dose
longer
treatment
interv
decreas
clinic
visit
frequenc
consid
goal
care
patient
respect
relief
symptom
improv
overal
surviv
evalu
patient
health
statu
respect
morbid
help
determin
treatment
determin
toxic
treatment
put
patient
risk
decreas
frequenc
visit
reduc
risk
less
frequent
schedul
oral
altern
older
patient
andor
medic
comorbid
significantli
increas
risk
morbid
mortal
contract
addit
gener
consider
mitig
infect
tabl
proven
benefit
adjuv
therapi
earli
stage
uterin
leiomyosarcoma
singl
agent
doxorubicin
requir
less
frequent
visit
may
repres
best
choic
limit
visit
treatment
oral
tyrosinekinas
inhibitor
pazopanib
approv
treatment
option
sarcoma
doxorubicin
ifosfamid
combin
gemcitabin
docetaxel
repres
mainstay
frontlin
treatment
patient
advanc
recurr
uterin
leiomyosarcoma
ulm
proven
benefit
adjuv
therapi
stage
stage
ii
ulm
advanc
recurr
ulm
gemcitabinedocetaxel
doublet
demonstr
activ
prior
trial
requir
administr
day
day
cycl
associ
signific
hematolog
toxic
includ
neutropenia
necessit
use
granulocyt
coloni
stimul
factor
singl
agent
doxorubicin
probabl
optim
firstlin
treatment
option
crisi
phase
iii
trial
compar
doxorubicin
q
day
combin
gemcitabin
docetaxel
everi
three
week
patient
unresect
metastat
soft
tissu
sarcoma
respons
rate
progressionfre
surviv
overal
surviv
similar
arm
dose
delay
dose
reduct
frequent
group
main
reason
febril
neutropenia
singleag
doxorubicin
frontlin
set
consid
balanc
risk
gemcitabinedocetaxel
patient
risk
cardiac
dysfunct
doxorubicin
crisi
pazopanib
oral
tyrosinekinas
repres
option
activ
ulm
aromatas
inhibitor
limit
toxic
result
stabl
diseas
patient
er
posit
ulm
noncur
therapi
toxic
risk
viral
infect
treatment
must
weigh
potenti
benefit
therapi
stage
grade
immatur
teratoma
follow
without
treatment
stage
dysgerminoma
follow
without
treatment
tumor
marker
includ
ldh
hcg
afp
check
exclud
mix
tumor
activ
surveil
could
consid
patient
complet
stage
stage
ia
grade
immatur
teratoma
risk
benefit
bleomycin
consid
due
concern
pulmonari
toxic
risk
respiratori
failur
malign
germ
cell
tumor
chemosensit
curabl
tumor
occur
young
healthi
patient
high
prioriti
resourc
limit
conserv
therapi
consid
complet
surgic
stage
includ
omentectomi
lymph
node
assess
critic
adjuv
therapi
omit
activ
surveil
grade
immatur
teratoma
current
investig
pediatr
studi
howev
indic
pediatr
tumor
may
less
aggress
biolog
stage
ia
yolk
sac
tumor
embryon
carcinoma
could
possibl
follow
without
treatment
extrem
resourc
limit
set
case
activ
surveil
tumor
marker
follow
make
sure
declin
appropri
bleomycin
caus
pulmonari
toxic
patient
concern
could
increas
risk
coexist
infect
bleomycin
safe
omit
dysgerminoma
detriment
surviv
base
experi
nonseminomat
testicular
cancer
relaps
rate
increas
bleomycin
includ
chemotherapi
regimen
therefor
risk
benefit
well
j
u
r
n
l
p
r
e
p
r
f
resourc
rate
viral
infect
care
consid
consid
chemotherapi
regimen
hysterectomi
consid
fertil
desir
reduc
need
chemotherapi
resourc
allow
second
c
result
remiss
patient
standard
methotrex
regimen
prefer
low
risk
gtd
oral
regimen
describ
low
risk
gtd
similar
efficaci
im
regimen
weekli
methotrex
consid
low
risk
diseas
dactinomycin
shown
efficaci
weekli
methotrex
patient
score
emaco
given
patient
score
even
though
regimen
requir
hospit
gtd
chemosensit
curabl
diseas
occur
premenopaus
patient
second
c
would
recommend
avoid
chemotherapi
patient
either
regimen
accept
women
score
regimen
requir
frequent
visit
inject
may
increas
exposur
viral
infect
small
seri
oral
regimen
describ
outcom
similar
report
methotrex
inject
could
consid
reduc
risk
exposur
infus
resourc
limit
dactinomycin
advantag
everi
week
dose
shown
superior
weekli
methotrex
howev
success
rate
regimen
women
score
gener
given
central
line
reduc
risk
extravas
injuri
regimen
continu
treatment
past
normal
hcg
defin
miuml
inpati
emaco
regimen
recommend
patient
j
u
r
n
l
p
r
e
p
r
f
high
risk
diseas
priorit
tier
studi
high
potenti
benefit
ie
trial
offer
drug
altern
treatment
limit
resourcestratifi
environ
identifi
inform
sponsor
deviat
visitslabsphys
examradiolog
test
essenti
pharmacokinet
test
awar
institut
regulatori
guidelin
regard
deviat
track
report
priorit
ship
oral
drug
patient
minim
inperson
visit
conduct
clinic
trial
crisi
challeng
vari
base
geograph
locat
institut
resourc
clinic
trial
guidelin
avail
fda
nation
cancer
institut
nrg
oncolog
local
institut
develop
guidelin
investigatoriniti
trial
intern
distribut
particip
site
clinic
trial
priorit
base
studi
type
benefit
potenti
tabl
patient
comorbid
condit
appear
higher
risk
sever
diseas
without
fatal
highest
person
year
old
rang
follow
among
person
age
year
among
person
age
year
among
person
age
year
fatal
among
person
age
year
recent
report
note
fatal
year
age
group
consid
oral
therapi
infusionbas
treatment
appropri
mind
oral
regimen
may
toxic
infusionbas
therapi
util
telemedicin
reduc
frequenc
person
evalu
allow
patient
proceed
directli
infus
center
treatment
obtain
local
collect
lab
whenev
possibl
consid
liber
use
granulocyt
coloni
stimul
factor
priorit
home
administr
use
pegfilgrastim
onbodi
injector
lieu
return
pegfilgrastim
day
consid
outpati
manag
neutropen
fever
clinic
stabl
moxifloxacin
mg
po
daili
ciprofloxacin
po
mg
bid
augmentin
mg
bid
po
maintain
close
followup
daili
phone
contact
least
day
ensur
clinic
deterior
delay
imag
complet
treatment
postcovid
surg
timefram
unless
critic
patient
immedi
care
ensur
goal
care
discuss
patient
includ
dnrdni
statu
priorit
prior
shortli
admiss
j
u
r
n
l
p
r
e
p
r
f
even
via
telephon
telemedicin
increas
interv
routin
port
flush
week
also
consid
dactinomycin
low
risk
gtd
reduc
number
visit
must
weigh
toxic
need
central
access
j
u
r
n
l
p
r
e
p
r
f
singl
agent
doxorubicin
q
wk
prefer
oral
low
threshold
avoid
radiat
unless
paclitaxelcarboplatin
aromatas
inhibitor
er
ulm
oral
pazopanib
